POST Online Media Lite Edition


Roche to invest 450 million Swiss Francs in China

Staff writer |
Roche will invest 450 million Swiss Francs over the next three years to establish a new diagnostic manufacturing facility at the Suzhou Industrial Park, in Suzhou, China.

Article continues below

The new manufacturing site sets out to address the continuously growing demand for diagnostic tests in China and the Asia Pacific region.

As a new addition to Roche's global diagnostic production network, the Asia manufacturing facility will focus on producing Immunochemistry and Clinical Chemistry tests, products that are crucial to clinical laboratory testing. The site plans to build a workforce of over 600 employees over the next several years.

"We are excited to expand our diagnostics value chain in China to include manufacturing,” Roland Diggelmann, COO of Roche Diagnostics, comments on the company's new Asia manufacturing facility.

"Roche is committed to investing in China and the Asia Pacific region. The new manufacturing site will enable us to meet the growing demand for our diagnostic products, ensuring our continuous contribution to the health of people in China and the Asia Pacific region.”

The new Roche Diagnostics manufacturing site will be the eighth worldwide and the first in the Asia Pacific Region. The facility will focus on packaging operations in the first phase and will be fully operational by 2018. The new site will not only strengthen the global manufacturing network of Roche Diagnostics, but also contribute to the company's strategy for sustaining its leadership position in the region.

Roland Diggelmann added: "We are confident that by establishing our manufacturing footprint here in Suzhou close to our China operations, we can further increase our market responsiveness and contribute to the overall competitiveness of our business.”

Roche Diagnostics has had a presence in Asia Pacific for 40 years and employs over 4,000 people, across 15 countries in the region

What to read next

Actelion in exclusive talks with Johnson & Johnson
Roche Group Q1 group sales up 5%
Lonza to buy U.S. capsule maker Capsugel for $5.5 billion